Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antigens, CD19 / genetics
  • Antigens, CD19 / immunology
  • CD28 Antigens / genetics
  • CD28 Antigens / immunology
  • Clinical Trials, Phase I as Topic
  • Cyclophosphamide / therapeutic use
  • Fatal Outcome
  • Gene Targeting*
  • Humans
  • Immunotherapy, Adoptive / adverse effects*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Lymphocyte Activation / immunology
  • Male
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • T-Lymphocytes / immunology
  • T-Lymphocytes / transplantation*

Substances

  • Antigens, CD19
  • CD28 Antigens
  • Recombinant Fusion Proteins
  • Cyclophosphamide